Search

everythinglearnresearchcommunity

for

Search:↓

Early treatment and multidisciplinary care are key to managing Frontal Fibrosing Alopecia and preventing further hair loss.

Some people with congenital triangular alopecia have a central tuft of hair in the bald patch, but the cause is unknown.

The article suggests that patients with Frontal Fibrosing Alopecia may have more contact allergies, but it doesn't prove that allergies cause the condition.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Eating disorders can cause skin problems, which may help with early diagnosis and treatment.

Frontal fibrosing alopecia in Bogotá mainly affects postmenopausal women, with possible links to hormonal changes and sunscreen use.

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Frontal fibrosing alopecia may affect nails and could be a type of lichen planus, treatable with certain medications.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Trichoscopy is a useful, quick, and non-invasive way to diagnose tinea capitis.

Deleting the Trf1 protein in mice is safe and may help prevent cancer without major side effects.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Mutations in the FOXN1 gene cause severe immune issues but don't affect hair and nails.

Tinea capitis can be quickly diagnosed and treated using dermoscopy to prevent hair damage.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

The article concludes that understanding Frontal Fibrosing Alopecia (FFA) is crucial for effective treatment, which includes medication like 5α-reductase inhibitors and hydroxychloroquine.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Hepatitis C treatment may cause frontal fibrosing alopecia.

A protein called sFRP4 from skin cells stops the development of pigment-producing cells in hair.

Recognizing trichofolliculomas is important to avoid unnecessary surgery.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Frontal fibrosing alopecia is a challenging hair loss condition with no known cause or definitive treatment.

A rare case of isolated trichothiodystrophy was identified, marked by brittle hair with low sulfur content.

Pseudofolliculitis barbae is a chronic skin condition affecting mainly African American and Hispanic individuals, caused by shaving tightly curled hair, and managed by prevention and treatment but not curable.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

The review suggests more research is needed to understand Frontal fibrosing alopecia, a condition causing hairline recession in postmenopausal women.

Most patients with frontal fibrosing alopecia are middle-aged women, often have thyroid disease, and some treatments can help stabilize the condition.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.